DexCom, Inc. (DXCM)
Should You Buy DexCom Stock Before Feb. 13?
DexCom (DXCM 1.51%) is a healthcare company that makes continuous glucose monitoring (CGM) devices, which help people track glucose levels.
Prediction: This Top Growth Stock Will Outperform the Market in the Next Decade
Medical device specialist DexCom (DXCM -0.90%) has substantially underperformed the market over the trailing-12-month period. The diabetes-focused company disappointed investors last year due to unimpressive financial results, especially in the second and third quarters.
DXCM's Preliminary Results Show Strong Growth: How to Play the Stock?
DexCom Inc. DXCM is off to a strong start in 2025, with its stock rallying 5.7% following the release of its preliminary results for the fourth quarter and fiscal 2024 on Jan. 13, 2025. The company's robust performance has reaffirmed investor confidence, driven by impressive revenue growth and a promising outlook for 2025.
DexCom: Fairly Priced In 2025; Why I'm Not Expecting A Share Price Comeback
DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, with muted enthusiasm from Wall Street today, and a "Hold" rating for me for 2025. I suspect the market overestimated DexCom's mass-market potential, leading to a reality check and a savage bear run on its stock in the past year.
2 Healthcare Stocks to Buy Hand Over Fist in January
Stocks tend to perform well in January, but that's not a good reason to invest this month. Strong returns aren't made in a single 30-day period.
DexCom Stock Up Following Strong Preliminary Q4 Results & 2025 Outlook
DXCM's top line reflects strong demand for its CGM sensors. International expansion is also driving sales higher.
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
DXCM continues to raise optimism among investors owing to its strong product portfolio.
Dexcom forecasts 2025 revenue mostly in-line with expectations
Dexcom forecast total annual revenue in line with Wall Street expectations on Monday, on bets of strong demand for its continuous glucose monitors for diabetes patients.
Abbott and DexCom settle glucose monitor patent disputes
Abbott Laboratories said on Monday it and DexCom have reached an agreement to settle all patent disputes between the companies related to continuous glucose monitoring devices.
DexCom (DXCM) Soars 5.6%: Is Further Upside Left in the Stock?
DexCom (DXCM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
1 Reason to Sell DexCom Stock, and 1 Reason to Buy
Shares of the medical-device maker DexCom (DXCM 5.57%) are down by 37% this year. The diabetes-focused healthcare company disappointed investors with its second-quarter results, leading to a massive drop in its stock price overnight.
DXCM Stock Gains on the Launch of Proprietary Generative AI Platform
Dexcom announces the first Generative AI platform in glucose biosensing.
